Dose-Response Effects of Bepridil in Patients With Persistent Atrial Fibrillation Monitored With Transtelephonic Electrocardiograms
—— A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (J-BAF Study) ——

Takeshi Yamashita, MD¹; Satoshi Ogawa, MD²; Toshiaki Sato, MD²; Yoshifusa Aizawa, MD³; Hirotsugu Atarashi, MD⁴; Akira Fujiki, MD⁵; Hiroshi Inoue, MD⁵; Makoto Ito, MD⁶; Takao Katoh, MD⁷; Youichi Kobayashi, MD⁸; Yukihiro Koretsune, MD⁹; Koichiro Kumagai, MD¹⁰; Shinichi Niwano, MD¹¹; Osamu Okazaki, MD¹²; Ken Okumura, MD¹³; Keijiro Saku, MD¹⁴; Teruhisa Tanabe, MD¹⁵; Hideki Origasa, PhD¹⁶ for the J-BAF Investigators

Background: A multicenter, randomized, placebo-controlled, double-blind trial was conducted with patients with persistent atrial fibrillation (AF) to determine the dose-response effects and safety of bepridil, using everyday transtelephonic monitoring.

Methods and Results: A total of 90 patients were randomized to receive placebo, 100 mg/day and 200 mg/day of bepridil treatment for 12 weeks. After the treatment, those patients who converted to sinus rhythm was 3.4% in placebo, 37.5% in those who received 100 mg/day and 69.0% in those who received 200 mg/day, thus demonstrating a linear dose-response relationship for AF conversion. The conversion rate gradually reached a maximal value at ~6 weeks after initiation of bepridil. However, the AF recurrence rate was high (91.7% in those receiving 100 mg/day and 75.0% in those receiving 200 mg/day). Adverse events, presumably related to the drug, were also frequent: ventricular tachycardia in 2, QT prolongation in 4 and sinus bradycardia in 2 patients. In those patients treated with 200 mg/day group, 1 patient died suddenly because of ventricular tachycardia.

Conclusions: This study demonstrated the dose-response-relationships of bepridil for AF conversion to sinus rhythm. However, the high rate of AF recurrence and substantial drug-related adverse effects, including sudden death, raised caution about using bepridil to treat persistent AF. The balance between benefits and risks of the drug should be individualized. (Circ J 2009; 73: 1020–1027)

Key Words: Atrial fibrillation; Bepridil; Clinical trial

Atrial fibrillation (AF), which is associated with increased mortality and morbidity¹–³ is a growing public health problem that has reached epidemic proportions.⁴,⁵ In Japan, the population of patients with persistent/permanent AF is estimated to be 0.73 million people in 2005 and is likely to increase to up to 1 million people in 2010.⁶ For the management of these increasing AF patients, many randomized clinical studies including the AFFIRM and I-RHYTHM studies have been performed, but failed to demonstrate the superiority of the pharmacological rhythm control to rate control strategy with respect to mortality and cardiovascular events in AF patients.⁸–¹⁰ One of the reasons for the result could be derived from inadequate antiarrhythmic effects and adverse effects of the drugs available at present. Actually, in the AFFIRM study, most patients assigned to the rhythm control strategy have been reported not to maintain sinus rhythm irrespective of aggressive treatment with amiodarone¹¹

Editorial p 1008

Bepridil was first developed as an anti-anginal drug, but afterwards, it has been reported to exert many electrophysi-
ologic effects on the heart by many experimental studies. In foreign countries, the antiarrhythmic effects of the drug were first examined based upon the experimental results in 1986. Although bepridil at a high dose of 600 mg/day was effective for converting AF to sinus rhythm, it frequently caused remarkable QT prolongation and life-threatening arrhythmias including torsades de pointes. The results estimated increased risks compared with the benefits, and therefore, the drug could not be used for AF treatment in the USA and Europe. In the 2000’s, several Japanese clinical studies reported that a low-dose bepridil (100–200 mg/day) was effective for converting persistent AF to sinus rhythm without causing any arrhythmogenic effects. Since then, some Japanese specialists in cardiac electrophysiology gradually began using a low-dose bepridil for persistent AF. However, those previous studies were performed in selected patients in selected institutions, and also in an open-label fashion. Therefore, it remains unknown how the results of low-dose bepridil can be applied to persistent AF in our clinical situations. Moreover, the results only analysed with periodical 12-lead electrocardiograms (ECG) could not identify the recurrence rate of AF after conversion to sinus rhythm. To validate the use of low-dose bepridil for persistent AF, it would be mandatory to solve these problems. The present study (J-BAF study) was planned as a physician-oriented clinical study to determine the dose-response effects of bepridil for conversion of persistent AF with every-day transtelephonic ECG monitoring in a multicenter, randomized, placebo-controlled, and double-blind method.

**Methods**

**Study Patients**

This clinical trial (J-BAF study) was a multicenter, randomized, placebo-controlled, parallel group study using bepridil in patients with persistent AF. In this study, persistent AF was defined as AF persisting for 7 days or longer ascertained on an every-day transtelephonic ECG. The following patients were excluded: (1) patients under 20 years of age; (2) patients with AF having been persisting for 1 year or longer; (3) patients within 1 month after cardiac surgery or acute myocardial infarction; (4) patients with AF presumably attributable to the following underlying disorders: sick sinus syndrome, giant left atrium (left atrial diameter ≥50 mm), severe conduction system disturbances, hyperthyroidism, or mitral stenosis; (5) patients with a left ventricular ejection fraction of <40% or with a Class III or IV heart failure; (6) patients with bradycardia (<50 beats/min); (7) patients with QT interval prolongation (QTc ≥460 ms); (8) patients with a history of syncope due to polymorphic ventricular tachycardia or antiarrhythmic drugs; (9) patients with severe hepatic or renal dysfunction; and (10) patients who were pregnancy or were lactating, and women of child-bearing potential.

**Study Design**

The study protocol was approved by the Institutional Review Boards at each center, and all patients gave written informed consent. During the 2 week observation period under placebo treatment, patients transmitted their ECG recordings for 30 s every day (at a particular time in each patient) and whenever symptoms where present using a transtelephonic monitor with a memory device (Cardiophone, Nihon-Koden, Tokyo, Japan) to the ECG center at Keio University Hospital. During this period, standard 12-lead ECG, chest X-rays, echocardiography, and blood/urine testing were also performed. After verifying that AF persisted for ≥7 days and patients were eligible for the enrollment, patients were randomized to any of the following three groups: (1) placebo; (2) 100 mg; or (3) 200 mg/day bepridil treatment. The test drugs and matching placebo, which were indistinguishable in size, weight, color and taste, were provided by Schering-Plough K.K. (Osaka, Japan). The treatment period lasted for 12 weeks, and, during this period, transtelephonic ECG common procedures were also performed every day and whenever symptoms were present to ensure precise ECG diagnosis. All ECGs were transmitted to the ECG center and also to each study center by facsimile to allow an assessment of safety for continuing the study. Twelve-lead ECG was also recorded on the first day and at 2, 4, 8, 12 weeks during the treatment period.

**Primary and Secondary End-Points**

The primary end-point of the present study was the conversion rate from persistent AF to sinus rhythm. The secondary end-points included AF recurrence after conversion to sinus rhythm, quality-of-life (QOL) improvement, and adverse effects by bepridil treatment. Sinus conversion and AF recurrence were evaluated with all ECGs recorded in each patient, including transtelephonic ECGs. For QOL assessment, 2 sets of questionnaires were used: the conventional SF-36 and the AFQLQ. The SF-36 (the Japanese version 2) consists of 8 subscales: (1) physical functioning; (2) role function-physical; (3) role function emotional; (4) bodily pain; (5) general health perceptions; (6) vitality; (7) social functioning (SF); and (8) mental health. The AFQLQ was invented by the Japanese Society of Electrocardiology as a QOL questionnaire specific for AF. It consists of 3 subscales: (1) the variety and frequency of symptoms (0–24 points); (2) the severity of symptoms (0–18 points); and (3) the limitations of daily and special activities and mental anxiety related to AF (0–56 points), where higher scores for each subscale indicate health status, as with SF-36.

**Statistical Analysis**

Data were presented as mean ± SD. Analysis of the efficacy end-point data was performed for the full analysis set (FAS) and per protocol set (PPS), and the analysis for the FAS was taken as a primary analysis. The statistical tests were 2-tailed with a significance level of 0.05 for the comparison of groups, and a significance level of 0.2 for the homogeneity in demographic data. Demographics and baseline characteristics of each group were summarized using descriptive statistics. Continuous variables were analyzed using 1-way analysis of variance with Bonferroni correction, and categorical variables were analyzed using the chi-squared test. The time point at which conversion to sinus rhythm was first noted on an ECG being taken as onset of the event, an intergroup comparison was made using the log-rank test. The frequency and percentage of patients with recurrence were calculated for each treatment group, and the intergroup comparison was made using the chi-squared test. As for QOL scores, an intergroup comparison was made using the t-test between the placebo group and the 100 mg/day group, between the placebo group and the
200 mg/day, and between the 100 mg/day group and the 200 mg/day group.

**Results**

**Patients Characteristics**

A total of 112 patients were recruited at 14 centers and 92 of them were randomly assigned to receive bepridil or placebo: 33 patients to receive 100 mg/day of bepridil, 29 patients to receive 200 mg/day, and 30 patients to placebo. The remaining 20 patients were withdrawn from the study during the observation period for the following reasons (Figure 1): deviation from inclusion criteria (n=11), withdrawal of informed consent (n=4), deviation from exclusion criteria (n=3), and other reasons (n=1). Of the 92 patients, 90 were eligible for the PPS and the FAS, and their baseline clinical characteristics are presented in Table 1. The mean age was ~63 years old, and male patients accounted for ~80% of the patients. Hypertension was present in approximately half of the patients. These characteristics resembled

### Table 1. Baseline Clinical Characteristics of the Study Patients

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=29)</th>
<th>100 mg/day (n=32)</th>
<th>200 mg/day (n=29)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>25 (86.2)</td>
<td>25 (78.1)</td>
<td>24 (82.8)</td>
<td>0.739*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62.7±9.1</td>
<td>63.5±13.0</td>
<td>64.6±8.5</td>
<td>0.802**</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68.1±13.7</td>
<td>66.8±15.5</td>
<td>67.8±14.4</td>
<td>0.928**</td>
</tr>
<tr>
<td>Duration of AF (days)</td>
<td>85.8±65.0</td>
<td>108.5±92.1</td>
<td>92.6±73.1</td>
<td>0.507**</td>
</tr>
<tr>
<td>Underlying disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>22 (75.9)</td>
<td>21 (65.6)</td>
<td>18 (62.1)</td>
<td>0.520*</td>
</tr>
<tr>
<td>Hypertension</td>
<td>14 (48.2)</td>
<td>20 (62.6)</td>
<td>16 (55.2)</td>
<td></td>
</tr>
<tr>
<td>Valvular disease</td>
<td>12 (41.3)</td>
<td>1 (3.1)</td>
<td>6 (20.7)</td>
<td></td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>1 (3.4)</td>
<td>5 (15.7)</td>
<td>2 (6.9)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>1 (3.4)</td>
<td>3 (9.4)</td>
<td>2 (6.9)</td>
<td></td>
</tr>
<tr>
<td>Echocardiographic parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD (mm)</td>
<td>42.6±6.6</td>
<td>43.9±4.5</td>
<td>43.4±5.0</td>
<td>0.642**</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>61.0±6.4</td>
<td>63.5±7.3</td>
<td>61.4±12.0</td>
<td>0.498**</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; LAD, left atrial dimension; LVEF, left ventricular ejection fraction. Data are mean±SD or number (%) of patients. *Fisher’s exact test, **one-way analysis of variance.
Bepridil and Atrial Fibrillation

Circulation Journal Vol.73, June 2009

those in the J-RHYTHM study recently performed in Japan.
Although the distribution of valvular disease and ischemic heart disease was somewhat inhomogeneous among the groups, the total prevalence of underlying diseases was not significantly different. Left ventricular systolic function was well preserved and the mean left atrial dimension was ~43 mm in each group. Twelve patients had a history of electrical cardioversion, which was reported to have failed only in 1 patient in the placebo group.

**Primary End-Point**
The number of patients in whom conversion to normal sinus rhythm was noted on ECG during the treatment period was 20 out of 29 patients (69.0%) for the 200 mg/day group, 12 out of 32 patients (37.5%) for the 100 mg/day group, and 1 out of 29 patients (3.4%) for the placebo group. Analysis for superiority of 200 mg/day and 100 mg/day groups verified a significant effect of bepridil in converting AF to sinus rhythm, compared with the placebo (chi-square test: \(P<0.001\) and \(P=0.001\), respectively). There were also significant differences between the 200 mg/day and 100 mg/day groups (chi-square test: \(P=0.014\)), thus demonstrating a clear dose–response relationship. An intergroup comparison with time-to-event analysis (Figure 2) also demonstrated statistically significant differences between the placebo and the 100 mg/day groups, between the placebo and the 200 mg/day groups, and between the 100 mg/day and the 200 mg/day groups (log-rank test: \(P=0.002\), \(P<0.001\) and \(P=0.002\), respectively). In both the 100 mg/day and 200 mg/day groups, the conversion rate reached to a maximal value at approximately 6 weeks after initiation of bepridil treatment.

**AF Recurrence After Conversion**
Although the conversion to sinus rhythm was frequently observed by bepridil treatment, the AF recurrence rate after conversion was high, irrespective of the continued treatment. AF did not recur during the 12-week treatment period in only 5 out of 20 patients (25.0%) that experienced sinus conversion in the 200 mg/day group and in 1 out of 12 patients (8.3%) in the 100 mg/day group. Conversely, 3 patients (15%) in the 200 mg/day group and 5 (41.7%) in the 100 mg/day group developed persistent AF lasting ≥7 days after transient conversion to sinus rhythm. In the remaining patients (12 out of 20 patients (60%) in the 200 mg/day group and 6 out of 12 patients (50%) in the placebo group, 1 responder experienced recurrence at 2 days after conversion to sinus rhythm. There were no significant differences in AF recurrence rate between the 100 mg/day and the 200 mg/day groups.

**QOL**
At the end of the treatment period, the 200 mg/day group showed statistically significant improvement compared with the placebo group in 2 subscales of AFQLQ (Figure 3, \(P=0.001\) in the variety and frequency of symptoms and \(P=0.002\) in the severity of symptoms). In the other subscale of the limitations of daily and special activities and mental anxiety, the 200 mg/day group showed a tendency towards improvement (\(P=0.052\)). Also, a statistically significant difference was observed between the 200 mg/day and the 100 mg/day groups with respect to the severity of symptoms (\(P=0.049\)). In contrast, there were no significant differences in all of the 8 subscales of the SF-36v2™ between the groups.

**Adverse Events by Bepridil (Table 2)**
The number of patients with adverse events during the study was 11 events in 7 of 29 patients (24.1%) from the 200 mg/day group, 8 events in 3 of 33 patients (9.1%) from the 100 mg/day group, and in 11 events in 6 of 30 patients (20.0%) from the placebo group. However, the most serious case with sudden cardiac death due to ventricular tachycardia was observed in 1 patient in the 200 mg/day group. The 59-year-old male patient with hypertension, diabetes mellitus and a history of percutaneous coronary intervention for angina developed syncope in the daytime on the 35th day after treatment, when the automatic external defibrillator recorded ventricular tachycardia; unfortunately he could not be rescued. When he was transferred to hospital, an ECG
showed a sinus rhythm without QT prolongation (QTc = 436), and the his serum K and Mg values were 4.2 and 2 mmol/L at the event, respectively. An autopsy could not reveal any organic lesions in any organs that could explain the unexpected death, suggesting that it could have resulted from cardiac rhythm disturbances. Moreover, adverse events with presumed causal relationships to the drug were frequently observed under bepridil treatment, for example, QT (QTc) interval prolongation >500 ms (4 patients in the 200 mg/day group), ventricular tachycardia (1 patient in the 200 mg/day group), and sinus bradycardia <50 beats/min (1 patient in both the 100 mg/day and 200 mg/day group). The 4 patients who showed remarkable QT prolongation after 200 mg bepridil treatment showed significantly longer RR intervals at baseline than the other patients, although gender, age and body mass index did not differ between them. For these reasons and others, drug administration had to be discontinued in 7 patients in the 200 mg/day group, 3 patients in the 100 mg/day group, and 2 patients in the placebo group. As for ECG variables, changes between the baseline and the end of treatment period were dose-related in respect to RR interval, QT interval, and JT interval (Table 3, simple regression analysis: P<0.001 in RR interval, P<0.001 in QT interval, P=0.002 and P<0.001 in QTc (Fridericia’s formula), respectively).

**Discussion**

**Major Findings**

The major findings of the present study were as follows: (1) There was a clear dose-response relationship between low-dose bepridil treatment and the conversion rate from persistent AF to sinus rhythm (38% in the 100 mg/day and 69% in the 200 mg/day group). The effects were also time-dependent and almost saturated at 6 weeks after treatment; (2) The AF recurrence rate after conversion, however, was high irrespective of the continued treatment (92% in the 100 mg/day and 75% in the 200 mg/day group); (3) 200 mg/day bepridil treatment significantly relieved the variety, frequency and severity of symptoms; (4) Sudden cardiac death due to ventricular tachycardia (1 patient) and remarkable QT prolongation (4 patients) was observed in 29 patients under the 12-week 200 mg/day treatment.

**Early Studies With Bepridil**

Although bepridil was first developed as an anti-anginal drug, the drug has been shown to affect many cardiac ion channels including Ca\(^{2+}\) channels and also many K\(^{+}\) channels by experimental studies\(^ {12-18}\). These electrophysiologic effects of bepridil led to it becoming an antiarrhythmic drug in the 1980s. The first trial with the drug for AF was reported in comparison with amiodarone\(^ {19}\). In this study, bepridil was used at a high dose of 400–600 mg/day for persistent AF, and the effects were compared to those produced by amiodarone, which was started at 800 mg/day and thereafter reduced to 200 mg/day. Nine of 14 patients were converted to sinus rhythm by the use of bepridil, while 4 of 10 were converted by amiodarone. Although the conversion rate by bepridil was remarkably high, serious adverse events were unexpectedly frequent: 2 patients developed torsades de pointes and other 4 patients experienced sustained ventricular tachycardia out of 14 patients under bepridil treatment. From the results, the authors concluded that the risks outweigh the benefits and bepridil does not offer an appreciable advantage over the established regimens or amiodarone. Actually, the FDA has not approved bepridil as an antiarrhythmic drug.
Studies With Low-Dose Bepridil

In Japan, 15 years after the first report, clinical experiences with the drug for AF have accumulated by specialists in field of cardiac electrophysiology. They used low doses of bepridil (100–200 mg/day) for minimizing arrhythmogenic side effects in patients with persistent AF, and found that even a low-dose bepridil was effective for the conversion of persistent AF to sinus rhythm (approximately 70%) in selected patients without causing arrhythmogenic effects. However, at the same time, several case reports also on the side effects of using low doses of bepridil: sick sinus syndrome with torsades de pointes or interstitial pneumonitis. Recently, a report with 459 AF patients has revealed that a low dose of bepridil caused adverse events in 19 patients (4%) (QT prolongation >0.55 s, bradycardia, and others) including torsades de pointes in 4 patients (0.9%). Therefore, the number of adverse effects were decreased by lowering the dose, but the fact that they occur should not be ignored.

It should be also pointed out that, in these studies with low-dose bepridil, the conversion rate and adverse events by bepridil were evaluated in an open-label fashion and in selected institutions which could not be free from many biases. In addition, the AF recurrence rate after conversion to sinus rhythm is still unknown, because the evaluation was based solely upon periodical standard 12-lead ECGs. The present multicenter study was planned to overcome the limitations of the previous studies, using randomization, placebo-control, double-blindness and every-day transtelephonic ECG monitorings.

Conversion and Recurrence Rate

The present study has clearly demonstrated the dose-response of bepridil effects on the conversion rate from persistent AF to sinus rhythm. The conversion rate by 200 mg/day reached approximately 70%, which is a high value consistent with the previous studies. In addition, the results, for the first time, clarified the treatment duration required for conversion. By using every-day transtelephonic ECG monitorings, the rate of sinus conversion gradually increased and reached a plateau at ~6 weeks after initiation of bepridil at either 100 mg/day or 200 mg/day. Therefore, the present study not only supported the results of the previous studies but also presented the appropriate time for assessing the drug efficacy. If an inefficiency was obtained within a 6-week treatment period, it would suggest that there would be little possibility of conversion if a longer administration was used.

Although the conversion rate by the drug was high, the recurrence rate after conversion was also high irrespective of the continued treatment. Only 5 patients out of 29 patients and 1 patient out of 32 patients experienced sinus conversion without AF recurrence in the 200 mg/day and 100 mg/day treated groups, respectively. Therefore, the present study demonstrated the effectiveness for AF conversion but could not demonstrate similar effects on AF prevention by using bepridil. The difference between the present study results and previous studies in respect to AF recurrence could be the result of the methods used for detecting AF recurrence. Only a standard 12-lead ECG is well known to miss the episodes of asymptomatic AF, and thus underestimate the rate of AF recurrence.

QOL

The QOL of AF patients is important for constructing a treatment strategy for AF. In the present study, in patients with persistent AF, QOL scores by AFQLQ were relatively high at baseline, as compared with a recent study involving AF patients undergoing catheter ablation. Nevertheless, 200 mg/day of bepridil significantly improved the 2 sub-scales of AFQLQ: the frequency and the variety, and severity of symptoms. These effects could be derived from sinus conversion by bepridil and also the heart rate control by the drug, which is known to have Ca2+ channel-blocking effects. In contrast, it should be remembered that the drug could not relieve the limitations of daily and special activities and mental anxiety related to AF, and did not improve SF-36 QOL scores. These results might be attributable to a high AF recurrence rate even under a continued treatment.

Adverse Events

As previous studies have demonstrated, arrhythmogenic effects by bepridil have been a great concern with its induced QT prolongation. Actually, in the present study, the drug administration had to be discontinued due to QT prolongation in 4 out of 29 patients (14%) undergoing a 200 mg/day treatment. This discontinuation rate seems somewhat higher than that in previous studies, and the difference might be attributed to the randomization and double-blindness of the present study.

The most important fact was that sudden cardiac death due to ventricular tachycardia was observed in 1 patient (3.4%, confidence interval 0.6–19.5%) in the 200 mg/day group. The history of ischemic heart disease of this patient might be related to this unexpected event. However, it should be noted that the lowest value of the confidence interval of the event rate almost corresponded with the rate of polymorphic ventricular tachycardia (0.9%) caused by low-dose bepridil, which was reported recently. Although polymorphic ventricular tachycardia is well known to be one of the bepridil-induced adverse events, a previous study has also reported that monomorphic ventricular tachycardia could also be caused by bepridil administration, which was almost identical to our case. A cohort study with Japanese AF patients has demonstrated that the cardiovascular mortality of AF patients is estimated to be approximately 1.3%/year and the mortality rate in the J-RHYTHM study was also low (0.6%/year). Based on these low mortalities of Japanese AF patients, excess death observed in the present study should be emphasized and in turn should also limit the use of this low-dose bepridil treatment. At the same time, tolerability for continuing the drug would be another concern, because 7 (24%) of patients under the 200 mg/day treatment group could not continue the study for various reasons including QT prolongation.

Primarily, many recent large clinical trials have demonstrated that there were no significant differences in the prognosis of patients with persistent AF between rhythm control and rate control strategies. The present study results with bepridil used in a rhythm control strategy should be interpreted in these situations, and the unignorable adverse events caused by the drug also supported the recent clinical evidence. Therefore, the present study does not promote the use of low-dose bepridil as treatment for persistent AF and rather demonstrates the requirement for even more caution, especially when the drug usage is necessary in some selected patients.
Study Limitations

The present study has several limitations. First, it used a relatively small number of the patients. However, we believe that the small number of patients did not mask the adverse effects by bepridil in the present study. Second is that the results were obtained only in patients with persistent AF and from a relatively short follow-up period. Therefore, the results should not be extrapolated to paroxysmal AF or to long-term bepridil treatment, because the study could not demonstrate the effectiveness and safety for AF prevention. Thirdly, it should be pointed out that bepridil dosages require careful reconsideration if it is to be used for AF treatment. Lastly, the present study enrolled only patients with preserved systolic function, and most of the patients were male. Therefore, the effects of bepridil in AF patients with decreased EF, congestive heart failure or in older female patients are totally unknown, particularly in regards to the adverse events. The present study could underestimate the adverse events in real-world medical practice, and therefore should not support bepridil usage for these patients.

Conclusions

The present study has demonstrated dose-dependent effectiveness of bepridil for conversion of persistent AF, but also identified the high rate of AF recurrence after conversion and also substantial adverse events by its arrhythmogenic effects. Although the drug might be an effective tool for AF conversion in some selected cases, the balance between benefits and risks is still arguable and, therefore, the usage should be individualized and closely monitored with caution, because the mortality of Japanese AF patients is quite low even under a standard rate control strategy.

References

Appendix

J-BAF Investigators
The following centers and investigators participated in this multicenter trial.

*Hirosaki University School of Medicine (Aomori):* Ken Okumura, Atsushi Iwasa, Masaomi Kimura.

*Keio University School of Medicine (Tokyo):* Satoshi Ogawa.

*Nippon Medical School (Tokyo):* Takao Katoh, Yoshinori Kobayashi, Yasushi Miyauuchi, Yu-ki Iwatsuki.

*Nippon Medical School Tama-Nagayama Hospital (Tokyo):* Hirotugu Atarashi, Eitaro Kodani, Makoto Matsumoto.

*The Cardiovascular Institute Hospital (Tokyo):* Takeshi Yamashita, Koichi Sagara, Takayuki Ohtsuka.

*Showa University School of Medicine (Tokyo):* Youichi Kobayashi, Taku Asano, Mitsuharu Kawamura.

*International Medical Center of Japan (Tokyo):* Osamu Okazaki.

*Tokai University School of Medicine (Kanagawa):* Teruhisa Tanabe, Koichiro Yoshioka, Yoshiaki Deguchi.

*Kitasato University School of Medicine (Kanagawa):* Shinichi Niwano, Masaru Yuge.

*Niigata University Graduate School of Medical and Dental Sciences (Niigata):* Yoshifusa Aizawa, Hiroshi Furushima.

*Faculty of Medicine, University of Toyama (Toyama):* Akira Fujiki, Koichi Mizumaki.

*Shiga University of Medical Science (Shiga):* Makoto Ito, Takashi Ashihara, Hideki Itoh, Yoshihisa Sugimoto.

*Osaka National Hospital (Osaka):* Yukihiko Koretsune.

*Fukuoka University Hospital (Fukuoka):* Keijiro Saku, Matsumoto Naomichi, Tomoo Yasuda.